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Introduction {#sec001}
============

The pathogenesis of the debilitating chronic skin disease hidradenitis suppurativa (HS) is still not well understood. A consistent observation is obstruction at the follicular infundibulum in apocrine gland bearing skin, and it seems possible that there are a number of initiating factors that could predispose to this development, reviewed in Hoffman et al. \[[@pone.0203672.ref001]\]. A proposed pathogenic pathway involves apocrine secretions accumulating in the hair follicle, which eventually ruptures onto the surface of the skin or into the dermis. Exposure to commensal bacteria then activates the innate immune system. Eventually the adaptive immune system is recruited. As this process is repeated, the inflammatory cascade leads to recurrent abscesses, suppurative dermal tunnels, and fibrosis. Important elements of the immune system that have been implicated include antimicrobial peptides (AMPs), Toll-like receptor 2 (TLR2), and cytokines such as IL-1, IL-6, IL-17, IL-12/23, and TNF. Many of the discoveries regarding HS to date have not been distinctive of HS, but reflect general cutaneous inflammatory responses to insults \[[@pone.0203672.ref002]\], along with a lack of resolution of the inflammatory process \[[@pone.0203672.ref003]\].

Even though a number of studies have contributed to defining the inflammatory milieu of HS by identifying potential individual biomarkers, only two publications describe the HS skin transcriptome \[[@pone.0203672.ref004], [@pone.0203672.ref005]\], and one evaluated the proteome in HS patients \[[@pone.0203672.ref006]\]. The skin microarray data by Blok et al. has previously been re-analyzed to show alteration of sphingolipid metabolism pathways in HS \[[@pone.0203672.ref007]\], as well as identification of novel therapeutics for HS \[[@pone.0203672.ref008]\]. However, mining from these powerful "hypothesis-free" omics platforms can still reveal novel pathways to evaluate.

In an effort to better understand HS disease progression and pathogenesis, we utilized a systems biology approach to integrate this omics data from a single cohort of HS patients presented in the two Blok et al. studies \[[@pone.0203672.ref004], [@pone.0203672.ref006]\] and a variety of bioinformatics techniques were used to mine the integrated data. In the HS skin transcriptome, we found abundant immunoglobulin and antimicrobial peptide genes, an interferon signature, and plasma cells were identified. The gene-set of the complement pathway was differentially activated across the HS skin and blood transcriptomes and the HS blood proteome. Furthermore, in the HS serum proteome, dysregulation of individual complement components was evident. These data suggest that an exuberant immune response may be driving HS chronicity. Although the factors responsible for this aberrant immune response are not yet elucidated, it is possible that dysbiotic cutaneous commensal bacteria may be playing a driving role in HS disease progression.

Materials and methods {#sec002}
=====================

Overview of data {#sec003}
----------------

Raw microarray and proteomic profiles were downloaded from Gene Expression Omnibus (GEO, GSE79150) using GEOQuery or raw proteomic data was obtained from the investigators of published studies \[[@pone.0203672.ref004]--[@pone.0203672.ref006], [@pone.0203672.ref009]\]. A summary of these studies, including number of patients, samples, lesions that were biopsied, and omic platform are in [S1 Table](#pone.0203672.s003){ref-type="supplementary-material"}. The data for analysis was from 17 patients with moderate-to severe HS, who had matching clinical data, skin and blood transcriptome and serum proteome ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page A) \[[@pone.0203672.ref004], [@pone.0203672.ref006]\]. An overview of patient demographic information can be found in [S2 Table](#pone.0203672.s004){ref-type="supplementary-material"}. There were two different groups of healthy volunteers for skin biopsies and blood. No demographic information is available for these healthy volunteers. Additional proteomic data were from patients with moderate-to-severe atopic dermatitis (AD), psoriasis (PS) and contact dermatitis (CD) \[[@pone.0203672.ref009]\].

Statistical analysis {#sec004}
--------------------

Statistical analysis was carried out using R-language ([R-project.org](http://r-project.org/)) and packages available through the Bioconductor project ([www.bioconductor.org](http://www.bioconductor.org/)). The study sample size was based on the design of the original studies. A homogeneous analytical pipeline was utilized.

Differences in profiles of gene and protein expression were assessed using linear mixed-effect models with tissue-type as a fixed factor, and patient as a random effect. Blood gene/protein expression profiles were compared between HS and healthy controls using linear models with disease-state. Models were fit in the *limma* package framework and hypothesis of interest were tested via contrasts using the moderated paired t-test \[[@pone.0203672.ref010]\]. P-values were corrected for multiple hypothesis testing and are presented with FDR values (significance level \<0.05).

Gene Set Variation Analysis (GSVA) is a pathway-based analysis approach that provides an overall pathway or gene-set activity score for each sample \[[@pone.0203672.ref011]\]. GSVA z-scores for Hallmark gene-sets from the Molecular Signature Database (MSigDB) (<http://software.broadinstitute.org/gsea/msigdb>) and other gene-sets were calculated from skin and blood transcriptome profiles using the GSVA package and compared across conditions using the same linear and mixed-effect models as the expression data. When calculating scores for proteomic data, gene identifiers of each gene name were converted to protein names prior to performing GSVA.

CIBERSORT allows an estimation of the abundance of immune cells for each sample using tissue gene expression profiles \[[@pone.0203672.ref012]\]. Levels of skin and blood immune cells were estimated from transcriptomic profiles using the CIBERSORT web app (<https://cibersort.stanford.edu/index.php>) and then analysed using the same analytic framework as described above. When comparing proteomic profiles from different studies (HS vs AD, PS and CD), batch adjustment was required, performed with the normal samples present in both studies using the R function *ComBat* from the *sva* package. PVCA analysis was used to assess that batch effect was correctly eliminated.

Results {#sec005}
=======

HS skin transcriptome was dominated by immunoglobulins, antimicrobial peptides (AMPs), an interferon signature, and plasma cells {#sec006}
--------------------------------------------------------------------------------------------------------------------------------

An overview of our integrative analysis is shown in [S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page A, and demographic features of the HS patients are presented in [S2 Table](#pone.0203672.s004){ref-type="supplementary-material"}. The microarray gene expression profiles from HS lesional (LS) skin to matched HS non-lesional (NL) skin were modelled to identify differentially expressed genes (DEGs) (FCH\>2.0, FDR\<0.05). The list of DEGs was refined to filter transcripts representing the same genes, and 422 (643 probes) unique upregulated DEGs and 310 (430 probes) downregulated DEGs were identified (FCH for all unique genes in [S4 Table](#pone.0203672.s006){ref-type="supplementary-material"}). This signature was similar to the prior published transcriptome \[[@pone.0203672.ref004]\].

The top 50 unique DEGs with the largest expression change between LS versus NL in the HS skin transcriptome are listed in [Table 1](#pone.0203672.t001){ref-type="table"}. Top upregulated DEGs in HS included immunoglobulin genes, AMPs (S100A7, A8, A9 and DEFB4), SERPINB3 and B4, CCL18, CXCL1, desmocollin 2 and fibrillin. Nine of the top 50 upregulated DEGs in HS were genes known to be upregulated in psoriasis (PS), including AMPs S100A7, A9, DEFB4, as well as SERPINB3 AND B4 \[[@pone.0203672.ref013]\]. Top downregulated DEGs in HS included sweat gland proteins, prolactin induced protein and dermcidin.
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###### Hidradenitis suppurativa skin transcriptome.

![](pone.0203672.t001){#pone.0203672.t001g}

  -------------------------------------------------------------------------------------------------------------------------------
  **Gene Name**                                                 **Symbol**   **logFCH**\   **FCH**\     **Pval**\    **FDR**\
                                                                             **LSvsNL**    **LSvsNL**   **LSvsNL**   **LSvsNL**
  ------------------------------------------------------------- ------------ ------------- ------------ ------------ ------------
  S100 calcium binding protein A7A                              S100A7A      4.85          28.9         4.40E-08     8.78E-06

  immunoglobulin heavy constant gamma 3                         IGHG3        4.35          20.43        1.07E-07     1.51E-05

  serpin family B member 4                                      SERPINB4     4.27          19.35        3.49E-06     0.000143

  defensin beta 4A \| defensin beta 4B                          DEFB4A       3.8           13.89        6.80E-07     4.77E-05

  S100 calcium binding protein A9                               S100A9       3.53          11.54        7.68E-09     3.10E-06

  ADAM like decysin 1                                           ADAMDEC1     3.49          11.22        8.25E-08     1.29E-05

  immunoglobulin kappa constant                                 IGKC         3.23          9.41         8.66E-06     0.000271

  tryptophan 2,3-dioxygenase                                    TDO2         3.13          8.75         2.13E-06     0.000102

  transcobalamin 1                                              TCN1         3.12          8.67         2.24E-05     0.000528

  aldo-keto reductase family 1 member B10                       AKR1B10      3.07          8.38         8.76E-10     9.27E-07

  serpin family B member 3                                      SERPINB3     3.01          8.03         2.51E-08     6.12E-06

  S100 calcium binding protein A8                               S100A8       2.97          7.83         8.27E-10     9.27E-07

  C-C motif chemokine ligand 18                                 CCL18        2.95          7.72         4.62E-07     3.74E-05

  immunoglobulin lambda variable cluster                        IGLV         2.9           7.46         0.000123     0.00173

  C-X-C motif chemokine ligand 1                                CXCL1        2.79          6.93         1.56E-06     8.28E-05

  immunoglobulin kappa variable 1D-13                           IGKV1D-13    2.77          6.82         3.65E-05     0.000732

  matrix metallopeptidase 12                                    MMP12        2.72          6.58         5.40E-05     0.000964

  peptidase inhibitor 3                                         PI3          2.66          6.31         7.23E-07     4.99E-05

  desmocollin 2                                                 DSC2         2.65          6.28         2.44E-06     0.000113

  SLAM family member 7                                          SLAMF7       2.6           6.05         3.25E-07     3.03E-05

  ADAM metallopeptidase domain 12                               ADAM12       2.58          6            5.69E-06     0.000201

  fibrillin 2                                                   FBN2         2.58          5.99         2.25E-08     5.67E-06

  immunoglobulin heavy constant delta                           IGHD         2.58          5.98         4.84E-05     0.000895

  keratin 16                                                    KRT16        2.57          5.93         5.38E-07     4.10E-05

  apelin receptor early endogenous ligand                       APELA        2.54          5.83         3.41E-10     6.99E-07

  prolactin induced protein                                     PIP          -5.36         -41.21       8.98E-11     3.12E-07

  dermcidin                                                     DCD          -5.22         -37.25       2.55E-07     2.55E-05

  secretoglobin family 2A member 2                              SCGB2A2      -4.88         -29.38       6.71E-07     4.72E-05

  adiponectin, C1Q and collagen domain containing               ADIPOQ       -4.5          -22.63       2.38E-11     1.76E-07

  thyroid hormone responsive                                    THRSP        -3.82         -14.09       4.21E-05     0.000815

  tetraspanin 8                                                 TSPAN8       -3.78         -13.76       1.03E-09     9.98E-07

  secretoglobin family 1D member 2                              SCGB1D2      -3.76         -13.52       7.20E-08     1.20E-05

  WNT inhibitory factor 1                                       WIF1         -3.71         -13.07       3.04E-11     1.76E-07

  perilipin 1                                                   PLIN1        -3.43         -10.78       2.05E-12     2.67E-08

  3-hydroxy-3-methylglutaryl-CoA synthase 2                     HMGCS2       -3.05         -8.27        1.43E-10     4.08E-07

  betacellulin                                                  BTC          -3.04         -8.21        3.65E-07     3.25E-05

  leucine rich repeat containing G protein-coupled receptor 5   LGR5         -3.02         -8.1         2.63E-09     1.72E-06

  complement C7                                                 C7           -2.79         -6.91        6.85E-07     4.79E-05

  fatty acid binding protein 7                                  FABP7        -2.75         -6.73        2.45E-05     0.000562

  fatty acid binding protein 4                                  FABP4        -2.61         -6.09        3.81E-08     7.86E-06

  Sp8 transcription factor                                      SP8          -2.56         -5.89        8.39E-08     1.29E-05

  ATPase H+ transporting V0 subunit a4                          ATP6V0A4     -2.52         -5.75        6.39E-05     0.00109

  hypoxia inducible factor 3 alpha subunit                      HIF3A        -2.43         -5.37        1.20E-08     3.99E-06

  claudin 8                                                     CLDN8        -2.41         -5.31        4.17E-05     0.000809

  erb-b2 receptor tyrosine kinase 4                             ERBB4        -2.4          -5.27        1.20E-06     6.95E-05

  semaphorin 3E                                                 SEMA3E       -2.4          -5.26        6.83E-08     1.18E-05

  suppressor APC domain containing 1                            SAPCD1       -2.35         -5.11        6.58E-13     1.14E-08

  fibroblast growth factor binding protein 2                    FGFBP2       -2.29         -4.9         5.60E-08     1.05E-05

  keratin 77                                                    KRT77        -2.29         -4.88        2.99E-05     0.000644

  carbonic anhydrase 6                                          CA6          -2.28         -4.86        2.23E-05     0.000525
  -------------------------------------------------------------------------------------------------------------------------------

To further understand the HS skin transcriptome, GSVA scores were compared between LS and NL skin to identify differential activity of Hallmark and other published gene-sets (FDR\<0.05; [S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page B). Gene-sets related to Notch signalling, Interferon alpha response, and Interferon gamma response showed the biggest changes in activity in LS versus NL skin. Gene-sets related to Complement and IL-6 JAK STAT3 signalling also showed a significant activation in LS skin.

GSVA scores were generated for up-regulated gene-sets in the following conditions, chosen for their potential relationship to pathogenesis ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page C): macrophage interferon signalling \[[@pone.0203672.ref014], [@pone.0203672.ref015]\]; IL-17 and TNF signalling in keratinocytes \[[@pone.0203672.ref016]\]; AD \[[@pone.0203672.ref017]\]; and PS \[[@pone.0203672.ref013]\]. All showed increased scores in HS skin. Nicastrin knockdown in keratinocytes induces type I interferon genes, but this gene-set was not differentially activated in the HS skin transcriptome ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page C).

The analysis of immune cell abundance estimated using CIBERSORT identified only plasma cells as more abundant in LS than NL skin (FDR\<0.05) ([Fig 1](#pone.0203672.g001){ref-type="fig"}).

![CIBERSORT analysis of HS skin transcriptome.\
(A) Heatmap showing normalized absolute abundance for each cell type in individual samples, mean abundance for each cell type is also displayed (left, green); (B) bar graph showing absolute abundance of each cell type in non-lesional (NL) and lesional (LS) samples; and (C) mean abundance of each cell type in all NL samples (left) and LS samples (right). Data from [S4 Table](#pone.0203672.s006){ref-type="supplementary-material"}. The abundance of plasma cells was significantly higher in LS versus NL skin (\*FDR \<0.05).](pone.0203672.g001){#pone.0203672.g001}

Minimal differences were observed in the HS blood transcriptome {#sec007}
---------------------------------------------------------------

The HS blood transcriptome was determined by comparing microarray gene expression of HS blood to that of healthy volunteers ([S5 Table](#pone.0203672.s007){ref-type="supplementary-material"}). There were no DEGs (FCH\>1.5, FDR\<0.05), which was similar to the observations of the prior investigators \[[@pone.0203672.ref004], [@pone.0203672.ref005]\]. However, despite null findings using the gene-based approach, the pathway-based approach identified global differential activation ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page D). Androgen response, protein secretion, and MTORC1 signalling were the top three differentially activated gene-sets, with Notch signalling and Complement gene-sets also showing increased scores in HS patients. This is described further in [S1 Text](#pone.0203672.s001){ref-type="supplementary-material"}. [S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page E presents the CIBERSORT analysis of the blood transcriptome.

HS blood proteome {#sec008}
-----------------

The HS blood proteome was determined by comparing expression of 1129 proteins in HS patients to that of healthy volunteers (SOMAscan platform). The prior analysis detected 54 dysregulated proteins, perhaps due to different modelling tools \[[@pone.0203672.ref006]\]. In our new analysis, there were 28 upregulated DEPs and 34 downregulated DEPs (FCH\>1.5, FDR\<0.05) (FCH for all proteins in [S6 Table](#pone.0203672.s008){ref-type="supplementary-material"}, DEPs shown in [Table 2](#pone.0203672.t002){ref-type="table"} and [S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page F). GSVA identified four differentially activated gene/protein-sets in this proteome (FDR\<0.05), namely MYC targets VI, Reactive oxygen species pathway, Adipogenesis, and Complement ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page G). There was no overlap between the HS transcriptome DEGs and HS serum proteome DEPs, although the Complement pathway was activated in all three analyses. The unique HS proteomic signature is described further in [S1 Text](#pone.0203672.s001){ref-type="supplementary-material"} and [S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page H. The lack of response of the HS blood proteome to ustekinumab treatment is described in [S1 Text](#pone.0203672.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0203672.t002

###### Hidradenitis suppurativa blood proteome.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **No.**   **Protein Name**                                             **Symbol**                                 **logFCH**\   **FCH**\    **Pval**\   **FDR**\
                                                                                                                    **HSvsN**     **HSvsN**   **HSvsN**   **HSvsN**
  --------- ------------------------------------------------------------ ------------------------------------------ ------------- ----------- ----------- -----------
  1         Glyceraldehyde-3-phosphate dehydrogenase                     GAPDH, liver/GAPDH                         3.62          12.32       4.68E-12    1.87E-09

  2         Pyruvate kinase PKM                                          M2-PK/PKM2                                 2.72          6.58        4.96E-12    1.87E-09

  3         GTP-binding nuclear protein Ran                              RAN/RAN                                    1.81          3.51        1.55E-06    0.000118

  4         Pulmonary surfactant-associated protein D                    SP-D/SFTPD                                 1.63          3.09        6.33E-05    0.00196

  5         Aflatoxin B1 aldehyde reductase member 2                     Aflatoxin B1 aldehyde reductase/AKR7A2     1.62          3.08        1.18E-06    0.000102

  6         Adenylate kinase isoenzyme 1                                 Myokinase, human/AK1                       1.36          2.56        0.000357    0.00683

  7         beta-adrenergic receptor kinase 1                            BARK1/ADRBK1                               1.32          2.49        1.90E-06    0.000126

  8         Importin subunit beta-1                                      IMB1/KPNB1                                 1.25          2.37        9.40E-05    0.00259

  9         C5a anaphylatoxin                                            C5a/C5                                     1.22          2.34        6.46E-06    0.000346

  10        Alpha-soluble NSF attachment protein                         SNAA/NAPA                                  1.19          2.29        1.31E-05    0.000592

  11        Heterogeneous nuclear ribonucleoprotein A/B                  hnRNP A/B/HNRNPAB                          1.15          2.23        4.94E-07    6.20E-05

  12        Proliferation-associated protein 2G4                         PA2G4/PA2G4                                1.03          2.04        1.74E-06    0.000123

  13        Heterogeneous nuclear ribonucleoproteins A2/B1               hnRNP A2/B1/HNRNPA2B1                      1.02          2.03        0.000311    0.0065

  14        Ras-related C3 botulinum toxin substrate 1                   RAC1/RAC1                                  0.94          1.92        1.41E-05    0.000611

  15        Carbonic anhydrase 1                                         Carbonic anhydrase I/CA1                   0.94          1.92        0.00124     0.0169

  16        Adenylosuccinate lyase                                       PUR8/ADSL                                  0.87          1.83        0.00459     0.0432

  17        N-acetyl-D-glucosamine kinase                                NAGK/NAGK                                  0.86          1.81        1.93E-05    0.000808

  18        Casein kinase II 2-alpha:2-beta heterotetramer               CK2-A1:B/CSNK2A1 CSNK2B                    0.8           1.74        0.0028      0.0296

  19        Mitogen-activated protein kinase 3                           ERK-1/MAPK3                                0.77          1.71        2.95E-05    0.00111

  20        Catalase                                                     Catalase/CAT                               0.77          1.71        0.00326     0.0332

  21        Rab GDP dissociation inhibitor beta                          Rab GDP dissociation inhibitor beta/GDI2   0.76          1.69        6.53E-05    0.00196

  22        Glycogen synthase kinase-3 alpha/beta                        GSK-3 alpha/beta/GSK3A GSK3B               0.73          1.66        6.48E-06    0.000346

  23        Ectonucleoside triphosphate diphosphohydrolase 5             ENTP5/ENTPD5                               0.65          1.57        2.57E-06    0.000152

  24        Stress-induced-phosphoprotein 1                              Stress-induced-phosphoprotein 1/STIP1      0.64          1.55        0.00108     0.0152

  25        X-ray repair cross-complementing protein 6                   Ku70/XRCC6                                 0.62          1.54        0.00433     0.0411

  26        Extracellular matrix protein 1                               ECM1/ECM1                                  0.62          1.53        0.00246     0.027

  27        Prostaglandin G/H synthase 2                                 COX-2/PTGS2                                0.59          1.51        7.99E-07    8.65E-05

  28        Proprotein convertase subtilisin/kexin type 7                PCSK7/PCSK7                                0.59          1.51        0.000212    0.00487

  1         Leukotriene A-4 hydrolase                                    LKHA4/LTA4H                                -3.06         -8.37       2.28E-10    6.45E-08

  2         Complement C3b                                               C3b/C3                                     -2.83         -7.09       4.82E-08    9.07E-06

  3         Follicle stimulating hormone                                 FSH/CGA FSHB                               -1.99         -3.98       0.000343    0.00667

  4         Dual specificity protein phosphatase 3                       DUS3/DUSP3                                 -1.78         -3.43       1.10E-08    2.49E-06

  5         Complement C4b                                               C4b/C4A C4B                                -1.64         -3.11       4.15E-05    0.00142

  6         Carbonic anhydrase 13                                        Carbonic anhydrase XIII/CA13               -1.62         -3.08       9.47E-07    8.91E-05

  7         Complement C3b, inactivated                                  iC3b/C3                                    -1.48         -2.79       7.66E-13    8.65E-10

  8         Human Chorionic Gonadotropin                                 HCG/CGA CGB                                -1.48         -2.78       0.00238     0.0269

  9         Luteinizing hormone                                          Luteinizing hormone/CGA LHB                -1.41         -2.65       0.00198     0.0231

  10        cAMP-dependent protein kinase catalytic subunit alpha        PRKACA/PRKACA                              -1.36         -2.57       8.43E-07    8.65E-05

  11        Tyrosine-protein phosphatase non-receptor type 11            SHP-2/PTPN11                               -1.28         -2.42       8.32E-08    1.17E-05

  12        Tyrosine-protein kinase Fyn                                  FYN/FYN                                    -1.1          -2.14       9.64E-05    0.00259

  13        Platelet glycoprotein VI                                     GPVI/GP6                                   -1.05         -2.07       6.75E-06    0.000346

  14        Inducible T-cell costimulator                                ICOS/ICOS                                  -1.01         -2.01       6.58E-05    0.00196

  15        Heat shock 70 kDa protein 1A/1B                              HSP 70/HSPA1A                              -0.98         -1.98       7.16E-08    1.16E-05

  16        NSFL1 cofactor p47                                           NSF1C/NSFL1C                               -0.99         -1.98       0.001       0.0143

  17        Tyrosine-protein kinase BTK                                  BTK/BTK                                    -0.92         -1.89       0.000328    0.00662

  18        C-C motif chemokine 28                                       CCL28/CCL28                                -0.9          -1.87       0.00404     0.039

  19        Tyrosine-protein kinase Fer                                  FER/FER                                    -0.87         -1.82       0.00109     0.0152

  20        Midkine                                                      Midkine/MDK                                -0.8          -1.75       0.000757    0.012

  21        Eukaryotic translation initiation factor 4 gamma 2           IF4G2/EIF4G2                               -0.79         -1.73       0.000786    0.0122

  22        Xaa-Pro aminopeptidase 1                                     XPNPEP1/XPNPEP1                            -0.76         -1.7        0.000104    0.00273

  23        Eukaryotic translation initiation factor 5                   eIF-5/EIF5                                 -0.77         -1.7        0.000257    0.00557

  24        Dual specificity mitogen-activated protein kinase kinase 2   MP2K2/MAP2K2                               -0.75         -1.68       0.00013     0.00334

  25        Myoglobin                                                    Myoglobin/MB                               -0.71         -1.64       1.24E-05    0.000584

  26        Growth/differentiation factor 2                              GDF2/GDF2                                  -0.68         -1.61       9.60E-06    0.000471

  27        Complement C3                                                C3/C3                                      -0.66         -1.59       0.000443    0.00782

  28        Translationally-controlled tumor protein                     TCTP/TPT1                                  -0.66         -1.58       0.00186     0.0221

  29        Clusterin                                                    Clusterin/CLU                              -0.61         -1.53       0.00014     0.00344

  30        Tissue Factor                                                TF/F3                                      -0.59         -1.51       4.00E-05    0.00141

  31        Kunitz-type protease inhibitor 2                             SPINT2/SPINT2                              -0.6          -1.51       0.000404    0.00737

  32        Glutathione S-transferase A3                                 GSTA3/GSTA3                                -0.6          -1.51       0.00548     0.0487

  33        NudC domain-containing protein 3                             NUDC3/NUDCD3                               -0.59         -1.5        1.57E-06    0.000118

  34        Cytoplasmic protein NCK1                                     NCK1/NCK1                                  -0.59         -1.5        2.15E-06    0.000135
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Complement pathway and components were dysregulated in the HS transcriptomes and blood proteome {#sec009}
-----------------------------------------------------------------------------------------------

*Complement* was a commonly identified Hallmark pathway in the HS skin and blood transcriptomes and HS blood proteome ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Pages B, D and F). In the context of the classical complement cascade, C5a was upregulated and C4b, C3, C3b and iC3b were downregulated in the HS blood proteome ([Fig 2](#pone.0203672.g002){ref-type="fig"}). In the skin transcriptome, C1q and C2 were elevated and C7 was decreased. Upregulated skin DEGs also included complement receptors CR1, C3aR1 and C5aR1. In the alternative complement pathway, Factor B was elevated, Factor D was reduced, and inhibitor Factor H was reduced in the skin. C3 and C5 were correlated with disease severity (p\<0.1) ([S1 File](#pone.0203672.s002){ref-type="supplementary-material"} Page J). The relationships between candidate serum biomarkers identified in the literature, and the skin transcriptome and blood proteome are discussed further in [S1 Text](#pone.0203672.s001){ref-type="supplementary-material"} and presented in [S8 Table](#pone.0203672.s010){ref-type="supplementary-material"}.

![Dysregulation of complement pathway components.\
Fold change of skin DEGs ([S4 Table](#pone.0203672.s006){ref-type="supplementary-material"}) (blue arrows) and blood DEPs ([Table 1](#pone.0203672.t001){ref-type="table"}) (red arrows) in the context of the complement cascade. It is not entirely clear which of the three complement activation pathways is engaged in HS, classical, lectin or alternative pathways. However, the classical pathway may be primarily implicated because of the involvement of C4 and the presence of immunoglobulins in the skin and blood. Additionally, lectin pathway activators, such as MBL and MASP, were not identified as DEGs in the skin or DEPs in the serum. Reprinted from Springe Nature under a CC BY license, with permission from Springe Nature, original copyright 2008. Modified by permission from Springer Customer Service Center GmbH: Springer Nature, Clinical and Basic Immunodermatology by Gaspari and Tyring, COPYRIGHT (2008).](pone.0203672.g002){#pone.0203672.g002}

Discussion {#sec010}
==========

Much remains to be learned about the cause of HS, and *omics* platforms provide extensive survey-type tools to unravel disease pathways and generate hypotheses. Our main findings in HS lesional skin were abundant immunoglobulin genes, AMP\'s, an interferon signature, and plasma cells. In this cohort of moderate-to-severe HS patients, the complement pathway was dysregulated in both the skin and blood. In the blood, there was an increase in C5a, with a reduction of components in the proximal part of the complement pathway (C3, C4, and iC3b). These new data are incorporated into a proposed pathogenic model in [Fig 3](#pone.0203672.g003){ref-type="fig"} with pathogenic elements unique to HS and those shared with other chronic skin diseases.

![Proposed pathogenesis of hidradenitis suppurativa.\
Pathogenesis of hidradenitis suppurativa (HS) can be considered in two phases, initiation and progression. Our analysis of advanced HS showed immunoglobulin (Igs) transcripts, antimicrobial peptides (AMPs), an interferon signature, plasma cells in lesional skin, and an association with complement dysregulation. Considered in the context of prior findings in HS such as numerous neutrophils, B cells, plasma cells, TLR2, and IL-32, there appears to be a concerted immune response (IR) to eradicate bacteria in HS. These efforts may drive HS disease progression. There are also data supporting general cutaneous immune responses such as abundant AMPs, pro-inflammatory cytokines including IL-1, IL-6, IL-17, IL-12/23, and a dysregulated Th17/T-reg cell axis (often seen in other chronic skin diseases such as psoriasis or atopic dermatitis).](pone.0203672.g003){#pone.0203672.g003}

While many inflammatory cell types have been identified in HS lesions, the most abundant were neutrophils and aggregates of CD20^+^ B cells \[[@pone.0203672.ref018]\], and CD138^+^ plasma cells have also been observed \[[@pone.0203672.ref019]\]. A polyclonal hyperglobulinemia in HS has been reported \[[@pone.0203672.ref020]\] which may be explained by the presence of cutaneous plasma cells. Our findings confirm that plasma cells and levels of immunoglobulin genes may be very abundant in HS, possibly to opsonize bacteria. The differential activation of interferon gene-sets also supports an anti-microbial host response in the skin. However, the role of the humoral immune system in HS has not yet been well characterized. There is a case report of an anti-B cell therapy being effective in HS \[[@pone.0203672.ref021]\].

Recently there has been a new appreciation for the functions of complement, one of the most evolutionarily conserved elements of the innate immune system \[[@pone.0203672.ref022], [@pone.0203672.ref023]\]. Complement has also been shown to be very important in maintenance of normal cutaneous commensal bacterial function \[[@pone.0203672.ref024]\]. Recently, serum complement has also shown to be elevated in HS \[[@pone.0203672.ref025]\] and may present a novel therapeutic target \[[@pone.0203672.ref026]\].

Complement dysregulation and plasma cells observed in HS may indicate a critical role of bacteria in HS disease progression. Bacterial culture, and more recently metagenomic analysis, have identified that most of the bacteria present in HS are normal commensal microbiota. *Porphyromonas* and *Prevotella* taxa, gram-negative anaerobic rods, appear to be abundant in HS lesions \[[@pone.0203672.ref027], [@pone.0203672.ref028]\]. *Porphyromonas gingivalis* has been studied in the context of periodontitis, and is considered a "keystone pathogen" in that disease \[[@pone.0203672.ref029]\]. The dominance of *Porphyromonas gingivalis* leads to a reduction of other commensal bacteria or "dysbiosis". One of the main mechanisms it utilizes to activate the immune system is via complement. Other elements of the host immune system are then recruited to try to eradicate these bacteria, including neutrophils, plasma cells and immunoglobulins.

Both *omics* and candidate approaches have their limitations: both are dependent upon the unique probes that are selected, and some cytokines may need more sensitive detection methods than the *omics* platforms \[[@pone.0203672.ref013]\]. Individual cytokines have been shown to be elevated in the serum of HS patients in some studies, including TNF \[[@pone.0203672.ref030]\], IL-17A \[[@pone.0203672.ref031]\], IL-6 \[[@pone.0203672.ref032], [@pone.0203672.ref033]\], and IL-32 \[[@pone.0203672.ref034]\]. Dysregulation of the Th17/Treg axis has been demonstrated in HS \[[@pone.0203672.ref035]\], and the "keratinocyte + IL-17" gene set was represented in the HS skin transcriptome in our analysis. IL-6 may be a driver of downstream systemic inflammation in HS inducing CRP, hepcidin and anaemia of chronic disease, immunoglobulins, Th17 differentiation, as well as contributing to other features seen in HS such as depression \[[@pone.0203672.ref036]\]. IL-32 is a novel cytokine produced by many immune cells, and was increased in HS compared to healthy controls, AD and PS \[[@pone.0203672.ref034]\]. Intracellular IL-32 has an important role in controlling intracellular infectious organisms, and secreted IL-32 can amplify immune responses by the induction of many cytokines including TNF, IL-1, IL-6, IL-23, IL-10, and Th1/17 cells \[[@pone.0203672.ref037], [@pone.0203672.ref038]\].

In summary, we have interpreted our findings of abundant immunoglobulin transcripts, AMPs, interferon signature, plasma cells, and complement dysregulation to indicate an effort by the immune system to control commensal bacteria in HS. Future investigations will test this hypothesis and hopefully lead to novel therapeutic approaches for this neglected disease.

Conclusion {#sec011}
==========

There is much to be learned by mining data from powerful "hypothesis-free" *omics* platforms. From a single cohort of HS patients in two studies \[[@pone.0203672.ref004], [@pone.0203672.ref006]\], we performed deep data analysis using advanced analytics such as GSVA and CIBERSORT. We identified abundant immunoglobulin transcripts, AMPs, an interferon signature, and plasma cells in HS lesions. There was also complement dysregulation in HS blood and skin. These findings suggest that HS disease is due to an exuberant inflammatory response which may be driven by dysbiotic commensal bacteria, and/or biofilms. Our findings led us to reconsider the role of bacteria in HS pathogenesis, and this may have important therapeutic implications.

Supporting information {#sec012}
======================

###### Additional results from analysis.

(PDF)

###### 

Click here for additional data file.

###### 

**Pages A-K**.

**Page A. Overview of analysis and integration of data, pathway analysis, and cellular composition predictive modeling.** The data for analysis was from 17 patients (pt) with moderate-to-severe hidradenitis suppurativa (HS), with matching clinical data, lesional skin (n = 17) and non-lesional skin (n = 13), and blood pre-treatment (pre) and post-treatment (post) with ustekinumab (described further in [S2 Table](#pone.0203672.s004){ref-type="supplementary-material"}). There were two different groups of ten healthy volunteers for blood samples (a and b). Fold change (FCH) for each analysis is provided as supplemental data for future analyses. \* Prior analysis published as list of differentially expressed genes (DEGs) (in Blok JL et al. 2016, ref \[[@pone.0203672.ref004]\]). Skin DEGs with FCH\>2.0 and FDR\<0.05 ("all") were filtered for a list of unique transcripts ("unique"). Differentially expressed proteins (DEPs; FCH\>1.5, FDR\<0.05) define the *HS disease proteome* ("all", 62 DEPs), and comparison with the proteome of other chronic skin diseases defines the *unique HS proteomic signature* ("unique" 16 DEPs). Gene Set Variation Analysis (GSVA) of Hallmark and other curated gene-sets, including psoriasis and atopic dermatitis was conducted. CIBERSORT is a platform to enumerate cellular composition from gene expression (Newman et al. 2015).

**Page B. Hallmark gene-sets in HS skin transcriptome.** Heatmap showing Gene Set Variation Analysis (GSVA) scores of Hallmark gene-sets with differential activation in lesional (LS) versus non-lesinal (NL) skin (FDR \<0.05) ([S4 Table](#pone.0203672.s006){ref-type="supplementary-material"}).

**Page C. Changes in HS, psoriasis (PS) and atopic dermatitis (AD) and associated gene-sets in the HS skin transcriptome.** Bar plots showing z-score log-fold change (+/-SD) of HS, PS and AD gene-sets in lesional (LS) versus non-lesional (NL) HS skin. Z-score changes for (A) gene-sets that are up-regulated and (B) down-regulated in HS, PS and AD. Asterix indicates significant difference in z-score LSvsNL. Gene-sets: Nicastrin knockout (NCSTN), macrophages + interferon (MACS+IFN), tissue IFN signature (IFN227), keratinocytes + IL-17 (KC+IL-17), keratinocytes + TNF (KC+TNF), psoriasis (PS), atopic dermatitis (AD). References for each gene-set are in the text. (\*\*\*FDR\<0.001).

**Page D. Hallmark gene-sets in HS blood transcriptome.** Heatmap showing Gene Set Variation Analysis (GSVA) scores of Hallmark gene-sets with differential activation in HS blood transcriptome versus normal volunteers (FDR \<0.05) ([S5 Table](#pone.0203672.s007){ref-type="supplementary-material"}).

**Page E. CIBERSORT analysis of HS blood transcriptome.** (A) Heatmap showing normalized absolute abundance for each cell type in individual samples, mean abundance for each cell type is also displayed (left, green); (B) bar graph showing absolute abundance of each cell type in Normal and HS samples; and (C) mean abundance of each cell type in all Normal samples (left) and HS samples (right). Data from [S5 Table](#pone.0203672.s007){ref-type="supplementary-material"}. There were no significant differences in proportion of cell types in this analysis.

**Page F. Expression of HS blood proteome in HS patients, at baseline and after treatment with ustekinumab, and healthy volunteers.** Heatmap showing differentially expressed proteins (DEPs) in HS versus normal volunteers (FCH\>1.5, FDR\<0.05), also listed in [Table 2](#pone.0203672.t002){ref-type="table"}. None of these DEPs changed significantly with ustekinumab treatment (FCH\>1.5, FDR\<0.05).

**Page G. Hallmark gene-sets in HS blood proteome.** Heatmap showing Gene Set Variation Analysis (GSVA) scores of Hallmark gene/protein-sets with differential activation in the blood proteome of HS patients versus normal volunteers (FDR \<0.05) ([S6 Table](#pone.0203672.s008){ref-type="supplementary-material"}).

**Page H. Determining the unique HS proteomic signature.** (A) Approach to determine unique HS proteomic signature compared to other skin diseases (from Wang *et al*, 2017). (B) Unique upregulated (green) and downregulated (red) differentially expressed proteins (DEPs) in moderate- to-severe hidradenitis suppurativa (HS) compared to atopic dermatitis (AD), psoriasis (PS), and contact dermatitis (CD) (FCH\>1.5, FDR\<0.05). (C) Unique genes of AD, PS, and CD (green) and shared upregulated genes of the three diseases (white). Of the six DEPs shared between AD, PS and CD, only C5a was upregulated across all four diseases. For AD, PS, and CD, DEPs that were identified as unique for each of these three diseases were not upregulated DEPs in HS vs normal.

**Page I. Analysis of the HS differentially expressed proteins** (**DEPs) in patients treated with ustekinumab who did not respond.** Heatmap showing 4 differentially expressed proteins (DEPs) in HS (responders n = 14; non-responders, Non-Res, n = 3) versus normal volunteers (n = 10) (FCH\>1.5, FDR \<0.05). In the comparison of pre-treatment (Pre) and post-treatment (Post) in non-responders, there were 4 HS DEPs that were differentially expressed on patients that did not respond to the treatment (FCH\>1.5, FDR\<0.05).

**Page J. Complement versus HS disease severity.** Scatter plots of disease activity in a cohort of HS patients (Hurley stage II and III) measured by modified Sartorius Score (mSS, range for these patients 8--241) versus complement differentially expressed proteins (DEPs). The patients were part of an ustekinumab clinical trial in HS, and serum proteins were measured at baseline (week 0) and after treatment (week 40). Normal volunteers are indicated with mSS = 0, but not included in the regression analysis. (A) serum C3, (B) serum C4, (C) serum C5 protein levels. Blue lines represent the linear fit for mSS score and expression/z-score, Pearson correlation coefficients (*r*) and p-values (*p*) are shown.

**Page K. Differentially expressed genes in HS lesional skin versus normal skin and status in HS lesional versus non-lesional skin.** Raw gene expression data from skin of de-roofed lesions (n = 7) versus normal skin (n = 6) on Illumina Human HT12 V4 bead Array (Hotz et al, JID, 2016, ref 5) was reanalyzed using the same approaches described in materials and methods. P-values were corrected for multiple hypothesis testing and are presented with FDR values (significance level \<0.05). The upregulated DEGs are listed, along with their status in lesional (LS) versus non-lesional (NL) skin (from [S4 Table](#pone.0203672.s006){ref-type="supplementary-material"}). Several genes did not have a corresponding target on the Affymetrix Chip.
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:   hidradenitis suppurativa
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:   false discovery rate

LS
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:   Gene Set Variation Analysis
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PS
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CD contact dermatitis
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